While the abundance of evidence indicating its significance in CIN and CIH imply NLRP3 to be a fascinating target for protective therapy, suppression of NLRP3 has also been associated with increased tumour resistance to cisplatin [121]. The gene discussed is NLRP3; the disease is cervical squamous intraepithelial neoplasia.